Sarepta Therapeutics
SRPT
178 hedge funds and large institutions have $1.08B invested in Sarepta Therapeutics in 2016 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 63 increasing their positions, 54 reducing their positions, and 51 closing their positions.
72.29% more ownership
Funds ownership: 0% → 72.29% (+72%)
17% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 54
9% more call options, than puts
Call options by funds: $212M | Put options by funds: $195M
5% less funds holding
Funds holding: 188 → 178 (-10)
16% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 51
58% less capital invested
Capital invested by funds: $2.6B → $1.08B (-$1.52B)
64% less funds holding in top 10
Funds holding in top 10: 11 → 4 (-7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Carlson Capital
Dallas,
Texas
|
+$88.5M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$59.4M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$27.9M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$21.6M |
| 5 |
CCM
Cadian Capital Management
New York
|
+$14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$77M |
| 2 |
Millennium Management
New York
|
-$64.8M |
| 3 |
JG
Jefferies Group
New York
|
-$59.3M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$39.3M |
| 5 |
Jennison Associates
New York
|
-$33.4M |
SRPT Hedge Fund Activity: Q4 2016 in Review
178 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q4 2016, worth a combined $1.08B — down 58% from $2.6B a quarter earlier.
Sellers outnumbered buyers: 51 funds closed out of SRPT and 43 opened new positions — a net loss of 8 holders — while 54 trimmed existing stakes and 63 added.
The largest buyer was Carlson Capital, opening a new position worth an estimated $88.5M. The largest seller was Point72 Asset Management, cutting an estimated $77M.
- 178 institutional investors held Sarepta Therapeutics (SRPT) as of Q4 2016, down from 188 in Q3 2016.
- Funds reported $1.08B of Sarepta Therapeutics stock for Q4 2016, down 58% quarter-over-quarter.
- 43 funds opened new Sarepta Therapeutics positions in Q4 2016 and 51 closed out, a net change of -8 holders.
- The largest Sarepta Therapeutics buyer in Q4 2016 was Carlson Capital, an estimated $88.5M added.
- The largest Sarepta Therapeutics seller in Q4 2016 was Point72 Asset Management, an estimated $77M sold.
Based on aggregated 13F filings for Q4 2016.